Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors
DNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA. Topoisomerase activity is particularly increased...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/9/8457 |
| _version_ | 1797602396382167040 |
|---|---|
| author | Jung Yoon Jang Donghwan Kim Nam Deuk Kim |
| author_facet | Jung Yoon Jang Donghwan Kim Nam Deuk Kim |
| author_sort | Jung Yoon Jang |
| collection | DOAJ |
| description | DNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA. Topoisomerase activity is particularly increased in rapidly dividing cells, such as cancer cells. Topoisomerase inhibitors have been an effective chemotherapeutic option for the treatment of several cancers. In addition, combination cancer therapy with topoisomerase inhibitors may increase therapeutic efficacy and decrease resistance or side effects. Topoisomerase inhibitors are currently being used worldwide, including in the United States, and clinical trials on the combination of topoisomerase inhibitors with other drugs are currently underway. The primary objective of this review was to comprehensively analyze the current clinical landscape concerning the combined application of irinotecan, an extensively investigated type I topoisomerase inhibitor for colorectal cancer, and doxorubicin, an extensively researched type II topoisomerase inhibitor for breast cancer, while presenting a novel approach for cancer therapy. |
| first_indexed | 2024-03-11T04:15:29Z |
| format | Article |
| id | doaj.art-b72de2800610484e973874a2363c985f |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T04:15:29Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b72de2800610484e973874a2363c985f2023-11-17T23:09:59ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-01249845710.3390/ijms24098457Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsJung Yoon Jang0Donghwan Kim1Nam Deuk Kim2Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of KoreaFunctional Food Materials Research Group, Korea Food Research Institute, Wanju-gun 55365, Republic of KoreaDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of KoreaDNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA. Topoisomerase activity is particularly increased in rapidly dividing cells, such as cancer cells. Topoisomerase inhibitors have been an effective chemotherapeutic option for the treatment of several cancers. In addition, combination cancer therapy with topoisomerase inhibitors may increase therapeutic efficacy and decrease resistance or side effects. Topoisomerase inhibitors are currently being used worldwide, including in the United States, and clinical trials on the combination of topoisomerase inhibitors with other drugs are currently underway. The primary objective of this review was to comprehensively analyze the current clinical landscape concerning the combined application of irinotecan, an extensively investigated type I topoisomerase inhibitor for colorectal cancer, and doxorubicin, an extensively researched type II topoisomerase inhibitor for breast cancer, while presenting a novel approach for cancer therapy.https://www.mdpi.com/1422-0067/24/9/8457topoisomerasesirinotecandoxorubicinclinical trialcombination chemotherapy regimens |
| spellingShingle | Jung Yoon Jang Donghwan Kim Nam Deuk Kim Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors International Journal of Molecular Sciences topoisomerases irinotecan doxorubicin clinical trial combination chemotherapy regimens |
| title | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors |
| title_full | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors |
| title_fullStr | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors |
| title_full_unstemmed | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors |
| title_short | Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors |
| title_sort | recent developments in combination chemotherapy for colorectal and breast cancers with topoisomerase inhibitors |
| topic | topoisomerases irinotecan doxorubicin clinical trial combination chemotherapy regimens |
| url | https://www.mdpi.com/1422-0067/24/9/8457 |
| work_keys_str_mv | AT jungyoonjang recentdevelopmentsincombinationchemotherapyforcolorectalandbreastcancerswithtopoisomeraseinhibitors AT donghwankim recentdevelopmentsincombinationchemotherapyforcolorectalandbreastcancerswithtopoisomeraseinhibitors AT namdeukkim recentdevelopmentsincombinationchemotherapyforcolorectalandbreastcancerswithtopoisomeraseinhibitors |